Abbott Japan Launches AccuGen HIV-1 Testing Agent
This article was originally published in PharmAsia News
Executive SummaryTokyo based Abbott Japan launched real-time polymerase chain reaction testing agent AccuGen m-HIV-1. Designed to be use with Abbott's m2000 rt analyzer, the testing agent is the first HIV RNA testing agent using real-time PCR. The product is able to test a wide range of virus loads. Abbott obtained manufacturing and marketing approval last November and received a NHI price listing last December. (Click here for more - Japanese language
You may also be interested in...
Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.
Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.